Mode
Text Size
Log in / Sign up
Phase 4 N=62 Randomized Single-blind Treatment

Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty

Pain, Postoperative · Total Knee Arthroplasty (TKA)

Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Mar 2018
Primary outcome: Primary: Time to Achieve Physical Therapy Discharge Criteria as Measured by 75-feet Walk Test. {Number of Hours After Conclusion of Surgery} — 67.3; 66; 46.5 Hours — p=0.355

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Continuous Femoral Nerve Block (Procedure); Nerve Block, Continuous Adductor Canal (Procedure); Continuous Sciatic Nerve Block (Procedure); Bupivacaine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Kevin King, DO
Primary completion
Aug 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Achieve Physical Therapy Discharge Criteria as Measured by 75-feet Walk Test. {Number of Hours After Conclusion of Surgery}
67.3; 66; 46.5 0.355
SECONDARY
Average Length of Stay (to be Reported in Hours After Surgery)
75.5; 74.3; 72.5 0.065
SECONDARY
Postoperative Pain, Average Reported Score 11-point Scale
3.961; 4.116; 4.282
SECONDARY
Sustained Straight Leg Raise
19; 14; 16; 0; 1; 0

Summary

Recently, several articles have suggested or reported that Adductor Canal Blocks (ACBs) offer adequate or equal analgesia and may promote better performance in early rehabilitation following Total Knee Arthroplasty (TKA) when compared to the more commonly used Femoral Nerve Block (FNB). A common feature of these studies has been the use of moderate to high concentration local anesthetics (e.g. 0.2% or 0.5% Ropivacaine respectively) which when injected by a large motor nerve will inevitably cause weakness. However, the practice at our institution has long been a continuous femoral nerve block (CFNB) with a lower concentration local anesthetic (0.0625% Bupivacaine). Over the past several years the investigators have performed several thousand CFNBs using this technique which has offered the advantage of minimal motor weakness and adequate analgesia. The primary goal of this study is to determine if our established practice of using a low concentration continuous FNB inserted about 5cm caudal to the groin crease (the apex of the femoral triangle) using a low infusion rate of 2ml/hr is comparable to the emerging practice of inserting a Continuous Peripheral Nerve Block (CPNB) in the anatomic adductor canal (AC) - infusing at 4ml/hr. A secondary goal is to study the effect of cumulative volume of local anesthetic infused through a FNB when at a rate of 2ml/hr compared to a rate of 4ml/hr in the 48-hour postoperative period. Definitions of the location of the adductor canal are debated heavily in literature, but they seem to agree that the middle 1/3 of the thigh contains the proximal AC while the distal 1/3 of the thigh contains the adductor hiatus - the terminal end of the AC. Our study will require placement of the continuous ACB no more distal than 20cm cephalad to the superior pole of the patella due to placement prior to surgery and the need to keep the dressing out of the operative field. The CACB catheter will also not be placed any more proximal than 20cm distal to the ASIS. In addition to other exclusion criteria, these measurements will create an exclusion for patients with an iliac-to-patella distance less than 40cm. Iliac to Patella distance (IPD) will be measured at the pre-operative interview on the day of surgery with a measuring tape. External palpable landmarks of the Anterior superior iliac spine and the superior pole of the patella will be used. The primary outcome is based upon the ability to perform rehabilitation exercises postoperatively to the extent that criteria for discharge can be met. The primary outcome measured is the time at which a patient gains the ability to successfully perform a 75-feet unassisted walk. On the Day of Surgery (DOS), prior to any walking attempt, a secondary outcome measure will be to perform a 5-second sustained straight leg raise. Other secondary outcomes will be the number of days admitted prior to discharge, and average pain scores on DOS, Postoperative Day (POD) #1, and POD#2. The Day of discharge will also be used as a secondary outcome. Earlier discharge is becoming a goal of almost all healthcare systems to minimize costs.

Eligibility Criteria

Inclusion Criteria

  • Able to consent to regional anesthesia and having primary total knee arthroplasty/replacement

Exclusion Criteria

  • Body-Mass Index >40
  • Iliac to Patella Distance (IPD) <40cm
  • Pre-existing quadriceps weakness of involved surgical side Chronic opioid use (if using opioids within 4 weeks of surgery: excluded)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02453321). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search